Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DNA
stocks logo

DNA

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
41.60M
-26%
--
--
43.93M
-50.66%
--
--
44.34M
+1.12%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Ginkgo Bioworks Holdings, Inc. (DNA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 11.30%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+11.30%
In Past 3 Month
5 Analyst Rating
up Image0
Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 9.00 USD with a low forecast of 6.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
3 Sell
Moderate Sell
up Image0
Current: 8.570
sliders
Low
6.00
Averages
9.00
High
12.00
up Image0
Current: 8.570
sliders
Low
6.00
Averages
9.00
High
12.00
TD Cowen
Brendan Smith
Strong Buy
Maintains
$3 → $10
2024-09-20
Reason
TD Cowen
Brendan Smith
Price Target
$3 → $10
2024-09-20
Maintains
Strong Buy
Reason
BTIG
Mark Massaro
Strong Sell
Maintains
$0.2 → $7
2024-08-23
Reason
BTIG
Mark Massaro
Price Target
$0.2 → $7
2024-08-23
Maintains
Strong Sell
Reason
Goldman Sachs
Matthew Sykes
Strong Sell
Maintains
$0.8 → $0.3
2024-07-09
Reason
Goldman Sachs
Matthew Sykes
Price Target
$0.8 → $0.3
2024-07-09
Maintains
Strong Sell
Reason
BTIG
Mark Massaro
Strong Sell
Maintains
$0.5 → $0.2
2024-06-26
Reason
BTIG
Mark Massaro
Price Target
$0.5 → $0.2
2024-06-26
Maintains
Strong Sell
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ginkgo Bioworks Holdings Inc (DNA.N) is -1.30, compared to its 5-year average forward P/E of -16.71. For a more detailed relative valuation and DCF analysis to assess Ginkgo Bioworks Holdings Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.71
Current PE
-1.30
Overvalued PE
13.99
Undervalued PE
-47.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-19.39
Current EV/EBITDA
-2.18
Overvalued EV/EBITDA
16.86
Undervalued EV/EBITDA
-55.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
13.82
Current PS
2.62
Overvalued PS
28.83
Undervalued PS
-1.19

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

DNA News & Events

Events Timeline

(ET)
2025-06-11
09:47:22
Ginkgo Bioworks rises 5.4%
select
2025-05-21 (ET)
2025-05-21
16:08:14
Ginkgo Bioworks says Steven Coen to replace Mark Dmytruk as CFO
select
2025-05-08 (ET)
2025-05-08
09:12:02
Twist Bioscience, Ginkgo Bioworks revise collaboration agreement
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.0
06-19NASDAQ.COM
Lobbying Update: $10,000 of GINKGO BIOWORKS lobbying was just disclosed

  • Ginkgo Bioworks Lobbying Disclosure: Ginkgo Bioworks disclosed $10,000 in lobbying expenses for Q2 2025, focusing on issues related to the Farm Bill, biosecurity, and biotechnology.

  • Insider Trading Activity: Over the past six months, insiders of DNA stock have sold shares 10 times with no purchases, while one institutional investor increased their holdings and four reduced theirs.

Preview
5.0
05-22PRnewswire
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

  • CFO Resignation and Successor Announcement: Ginkgo Bioworks' Chief Financial Officer, Mark Dmytruk, will resign on May 30, 2025, to pursue another opportunity, with Chief Accounting Officer Steven Coen set to take over the CFO role.

  • Leadership Transition Remarks: Both Dmytruk and CEO Jason Kelly expressed gratitude for Dmytruk's contributions, while Coen emphasized his readiness to continue advancing the company's financial goals.

Preview
9.5
05-07Yahoo Finance
Ginkgo Bioworks Reports First Quarter 2025 Financial Results

  • Financial Performance Update: Ginkgo Bioworks reported a total revenue of $48 million for Q1 2025, marking a 27% increase from the previous year, with a net loss reduced to $(91) million compared to $(166) million in Q1 2024. The company is on track to achieve $250 million in cost reductions by Q3 2025.

  • Strategic Developments: Ginkgo has secured a $29 million contract from ARPA-H for developing essential medicines and is expanding its role as an R&D service provider for the US government and biopharma sectors, with a significant backlog of projects valued at approximately $180 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA) stock price today?

The current price of DNA is 8.57 USD — it has decreased -0.12 % in the last trading day.

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA)'s business?

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.

arrow icon

What is the price predicton of DNA Stock?

Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 9.00 USD with a low forecast of 6.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA)'s revenue for the last quarter?

Ginkgo Bioworks Holdings Inc revenue for the last quarter amounts to 48.32M USD, increased 27.34 % YoY.

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA)'s earnings per share (EPS) for the last quarter?

Ginkgo Bioworks Holdings Inc. EPS for the last quarter amounts to -1.68 USD, decreased -49.24 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ginkgo Bioworks Holdings Inc (DNA)'s fundamentals?

The market is revising No Change the revenue expectations for Ginkgo Bioworks Holdings, Inc. (DNA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 11.30%.
arrow icon

How many employees does Ginkgo Bioworks Holdings Inc (DNA). have?

Ginkgo Bioworks Holdings Inc (DNA) has 834 emplpoyees as of June 23 2025.

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA) market cap?

Today DNA has the market capitalization of 475.91M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free